Close
Help
signup_email_alerts
Need Help?



Effects of Celecoxib and Ly117018 Combination on Human Breast Cancer Cells in Vitro

Submit a Paper


Libertas Analytics


3119 Article Views

Publication Date: 07 Apr 2009

Journal: Breast Cancer: Basic and Clinical Research

Citation: Breast Cancer: Basic and Clinical Research 2009:3 23-34

BCbcr journal

144,101 Article Views

6,649,611 Libertas Article Views

More Statistics

Abstract

Activation and signalling of estrogen receptor (ER) and COX-2 represent two important pathways in breast cancer cell regulation. Activation of either pathway is associated with breast cancer cell proliferation and eventually malignant progression. Raloxifene analogue, Ly117018, a selective estrogen receptor modulator and celecoxib, a specific COX- 2 inhibitor have been shown to inhibit breast cancer cell proliferation when used alone in vitro and in vivo. In this study, the combined drug effects on hormone-dependent MCF-7 and hormone-independent MDA-MB-435 cells in vitro were evaluated. Cell proliferation assays excluded drug antagonism and revealed a moderate synergistic growth inhibitory activity of Ly117018 and celecoxib on both cell lines when combined in specific concentrations. Growth inhibition of either compound was not associated with cell cycle arrest. In MCF-7 cells, western blot analysis revealed a decreased phosphorylation of the AKT protein by either agent alone or in combination. In MDA-MB-435 cells, celecoxib alone induced an increase in AKT phosphorylation relative to total AKT protein; this effect was decreased in the presence of Ly117018. These results indicate that these two drugs are non-antagonistic; and when combined in specific concentrations, moderate synergistic antiproliferative activity of celecoxib and Ly117018 were observed in hormone-dependent MCF-7 and hormone- independent MDA-MB-435 cells associated with changes in cell cycle distribution and regulation of AKT protein and phosphorylation. These findings further support a central role of the ER- and COX-2 pathways in human breast cancer cells.


Post a Comment

x close

Discussion Add A Comment
No comments yet...Be the first to comment.


share on

Our Service Promise

  • Prompt Processing (Less Than 3 Weeks)
  • Fair & Comprehensive Peer Review
  • Professional Author Service
  • Leading Editors in Chief
  • Extensive Indexing
  • High Readership & Impact
  • What Your Colleagues Say

Quick Links

Follow Us We make it easy to find new research papers. RSS Feeds Email Alerts Twitter

BROWSE CATEGORIES
Our Testimonials
Publishing in Gene Regulation and Systems Biology was a very positive experience.  I was impressed by the fast and uncomplicated submission process as well as the clear and professional peer review process which helped to improve the manuscript.  The Libertas Academica team was very patient and helpful.  I would definitely recommend the journal to other colleagues in the field!
Dr Cameron Moshfegh (Federal Institute of Technology, Switzerland) What Your Colleagues Say